Aldeyra Therapeutics Stock Is Trading Higher On Acing Allergic Conjunctivitis Study With Reproxalap
- Aldeyra Therapeutics Inc (NASDAQ: ALDX) has announced positive top-line results from the Phase 3 INVIGORATE trial evaluating 0.25% reproxalap, in patients with allergic conjunctivitis.
- The 95-subject trial achieved statistical significance for the primary endpoint and all secondary endpoints.
- The primary efficacy endpoint was the change from baseline in subject-reported ocular itching score after allergen chamber entry. The key secondary endpoint was the change from baseline in ocular redness over the duration of the allergen chamber (approximately 3.5 hours).
- Relative to patients treated with vehicle, patients treated with reproxalap reported statistically significant ocular itching score reduction across all 11 prespecified primary endpoint comparisons (p<0.0001 for each comparison).
- The reproxalap-treated patients demonstrated a statistically significant reduction in ocular redness over the duration of the allergen chamber.
- The company is also conducting TRANQUILITY trials in dry eye disease, with data expected in the second half of 2021.
- Aldeyra plans to meet with the FDA in the second half of 2021 to discuss the INVIGORATE results and the potential submission of a marketing application.
- Reproxalap is a novel small-molecule immune-modulating covalent inhibitor of RASP elevated in ocular and systemic inflammatory disease.
- The company will host a conference call at 8:00 a.m. ET today.
- Price Action: ALDX shares are up 31.9% at $14.65 in premarket trading on the last check Tuesday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Allergic Conjunctivitis BriefsBiotech News Health Care Small Cap General
